Fibroblast Growth Factor Receptor Inhibitor
Showing 1 - 25 of >10,000
Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)
Recruiting
- Urothelial Carcinoma
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 8, 2023
Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)
Active, not recruiting
- Squamous-cell Non-small Cell Lung Cancer
-
Baden, Switzerland
- +10 more
Jan 20, 2022
Tumors Trial in Worldwide (Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib
Completed
- Neoplasms
- Rogaratinib (BAY1163877) oral solution
- +2 more
-
Chicago, Illinois
- +28 more
Apr 12, 2021
Serum Fibroblast Growth Factor-21 Levels During Prolonged
Completed
- Fibroblast Growth Factor-21
- Fasting
- 12 hour fasting for 29 days
-
Ankara, TurkeyHacettepe University Nutrition and Dietetics Department
Mar 29, 2023
Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)
Withdrawn
- Bladder Transitional Cell Carcinoma
- +2 more
- (no location specified)
Aug 8, 2022
Fibroblast Growth Factor 21, Tast Perference Trial (Fibroblast growth factor 21 infusion, Placebo infusion (saline))
Active, not recruiting
- Fibroblast Growth Factor 21
- Tast Perference
- Fibroblast growth factor 21 infusion
- Placebo infusion (saline)
-
Hellerup, DenmarkAmalie R Lanng
Nov 21, 2022
Fibrous Dysplasia Of Bone Trial run by the National Institute of Dental and Craniofacial Research (NIDCR) (Burosumab)
Not yet recruiting
- Fibrous Dysplasia Of Bone
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 24, 2022
Fibroblast Growth Factor 23 and Sclerostin in Relation to
Not yet recruiting
- COVID-19
- Calcium
- +3 more
-
Aswan, EgyptAswan University hospital
Mar 11, 2022
Recurrent Glioblastoma Trial (Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T
Not yet recruiting
- Recurrent Glioblastoma
- Targeted Epidermal Growth Factor Receptor Variant III(EGFRvIII) autochimeric antigen receptor T cell injection
- (no location specified)
Apr 4, 2023
NAFLD Trial in Ahvaz (Soy isoflavone, Placebo)
Completed
- NAFLD
- Soy isoflavone
- Placebo
-
Ahvaz, Khuzestan, Iran, Islamic Republic ofAsal Neshatbini Tehrani
Oct 24, 2023
OPTImal PALliative Anti-epidermal Growth Factor Receptor
Active, not recruiting
- Colorectal Cancer Metastatic
- +5 more
- Plasma circulating DNA analysis
-
Aarhus, DenmarkAarhus University Hospital
Feb 24, 2022
Healthy Trial in Frederiksberg (Sucrose, Sucrose + protein, Sucrose + fat)
Completed
- Healthy
- Sucrose
- +2 more
-
Frederiksberg, DenmarkDepartment of Nutrition, Exercise and Sports, University of Cope
Mar 30, 2022
Fibroblast Growth Factor 23 in Chronic Respiratory Failure
Not yet recruiting
- Chronic Respiratory Failure
- Dosage
- Cardiac echography
- (no location specified)
Feb 17, 2022
NSCLC (NSCLC) Trial (Osimertinib, Amivantamab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Mar 24, 2023
NSCLC, Epidermal Growth Factor Receptor, Leptomeningeal Metastasis Trial (Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- +2 more
- (no location specified)
Mar 27, 2023
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Trial in
Recruiting
- Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
-
Canton, OhioGabrail Cancer and Research Center
Jul 21, 2023
Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal Trial in Los Angeles, Bethesda (Dasatinib, Ganitumab)
Terminated
- Rhabdomyosarcoma
- +2 more
-
Los Angeles, California
- +1 more
Mar 17, 2022
Patients Who Received EGFR-TKI for the Treatment of NSCLC and Developed Paronychia (Affecting Fingernails, Toenails or Both)
Recruiting
- Patients Who Received EGFR-TKI for the Treatment of Non-small Cell Lung Cancer and Developed Paronychia (Affecting Fingernails, Toenails or Both)
- Topical Timolol
-
Hong Kong, Hong KongQueen Mary Hospital
Nov 14, 2023
Gestational Diabetes Trial in ChiangMai (blood draw)
Active, not recruiting
- Gestational Diabetes
- blood draw
-
ChiangMai, ThailandMaharaj Nakorn ChiangMai Hospital
Dec 1, 2022
Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)
Recruiting
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Docetaxel
- +3 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in
Recruiting
- Locally Advanced Gastrointestinal Stromal Tumor
- +7 more
- Biopsy
- +4 more
-
Duarte, California
- +17 more
Feb 2, 2023
Metastatic Breast Cancer Trial in Spain (Pembrolizumab, Paclitaxel)
Active, not recruiting
- Metastatic Breast Cancer
-
Hospitalet de Llobregat, Barcelona, Spain
- +6 more
Jan 23, 2023